caus
agent
sever
threat
global
health
patient
infect
show
wide
rang
symptom
diseas
sever
limit
data
avail
immunogen
kinet
develop
antibodi
respons
relat
clinic
featur
dynam
specif
bcell
popul
report
immunophenotyp
b
cell
perform
flow
cytometri
longitudin
collect
pbmc
parallel
serum
sampl
analyz
presenc
iga
igg
igm
antibodi
use
whole
proteom
peptid
microarray
soon
diseas
onset
mild
case
observ
increas
frequenc
plasmablast
concomitantli
strong
iga
respons
contrast
case
sever
progress
show
delay
eventu
strong
broad
iga
respons
case
studi
show
determin
antibodi
epitop
valuabl
monitor
specif
magnitud
earli
bcell
respons
could
guid
develop
vaccin
candid
followup
studi
requir
evalu
whether
kinet
strength
iga
respons
could
potenti
prognost
marker
viral
control
novel
coronaviru
first
describ
wuhan
china
januari
caus
agent
three
coronavirus
includ
known
cross
speci
barrier
infect
human
besid
sarscov
merscov
pathogen
human
caus
sever
ill
death
potenti
epidem
pandem
spread
world
health
organ
classifi
three
virus
prioriti
pathogen
acceler
develop
vaccin
therapeut
prevent
epidem
betacoronaviru
show
genet
similar
sarscov
highli
infecti
spread
fast
current
pandem
proport
four
month
sinc
initi
detect
million
peopl
infect
global
die
infect
present
differ
symptom
wide
spectrum
sever
patient
fever
cough
radiolog
abnorm
initi
present
patient
experi
fever
cough
other
display
sever
form
diseas
lead
bilater
pneumonia
treat
intens
care
unit
sometim
lead
death
better
understand
immunogen
pathobiolog
infect
human
urgent
need
basi
develop
diagnost
therapeut
vaccin
highdens
peptid
array
enabl
rapid
identif
antigen
epitop
recogn
antibodi
mani
applic
pathogenspecif
peptid
array
help
identifi
biomark
earli
detect
diseas
develop
therapeut
ration
design
vaccin
identif
epitop
target
protect
antibodi
critic
develop
monoclon
antibodi
therapeut
use
highdens
peptid
array
combin
clinic
immunolog
data
provid
insight
immunogen
induc
focu
antibodi
develop
infect
screen
patientspecif
iga
igg
igm
respons
full
viral
proteom
map
overlap
linear
peptid
array
fast
provid
data
identifi
new
diagnost
marker
shed
light
unknown
immunolog
interact
report
longitudin
bcell
popul
virusspecif
antibodi
respons
data
two
patient
marri
coupl
husband
sever
cours
diseas
hospit
ventil
wife
began
experi
mild
symptom
six
day
husband
subsequ
diagnos
addit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
identifi
biomark
diseas
progress
discov
import
epitop
vaccin
develop
blood
four
patient
one
healthi
control
collect
univers
medic
center
hamburgeppendorf
donor
provid
written
inform
consent
protocol
approv
ethic
committe
hamburg
medic
associ
germani
peripher
blood
mononuclear
cell
pbmc
isol
cryopreserv
edtablood
use
standard
oper
procedur
via
ficol
densiti
gradient
centrifug
serum
sampl
aliquot
store
see
tabl
bcell
immunephenotyp
conduct
cryopreserv
pbmc
stain
panel
depict
support
inform
tabl
cell
analyz
bd
lsrfortessa
evalu
whole
proteom
genbank
id
map
spot
overlap
peptid
later
shift
two
aa
peptid
microarray
obtain
pepperprint
gmbh
heidelberg
germani
patient
sera
dilut
incub
array
overnight
afterward
igg
igm
iga
serum
antibodi
interact
differenti
detect
fluoresc
label
secondari
antibodi
detail
see
support
inform
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
collect
blood
differ
time
point
post
symptom
onset
tabl
use
flow
cytometri
peptid
microarray
evalu
detail
kinet
antibodi
develop
patient
male
develop
gener
weak
myalgia
headach
intermitt
episod
high
fever
subsequ
product
cough
two
day
first
symptom
test
posit
rtpcr
point
time
fever
alreadi
subsid
low
grade
temperatur
recur
second
week
increas
creactiv
protein
mgdl
oral
treatment
betalactamas
antibiot
start
patient
hospit
four
day
show
moder
typic
ground
glass
opac
highresolut
thorax
comput
tomographi
scan
fulli
recov
without
ventil
support
even
though
patient
requir
intens
care
treatment
ventil
symptom
moderatesever
defin
patient
sever
case
patient
due
hospit
patient
wife
femal
test
posit
six
day
husband
first
symptom
high
viral
shed
monitor
rtpcr
although
report
mild
clinic
symptom
subfebril
temperatur
mild
cough
constant
sens
wellb
pfefferl
et
al
submit
patient
includ
control
test
posit
mild
mildmoder
cours
diseas
without
hospit
sampl
serv
neg
control
dynam
immun
respons
analyz
flow
cytometri
use
pbmc
memori
bcell
popul
increas
follow
infect
approxim
day
post
diseas
onset
patient
fig
b
persist
sever
case
expans
plasmablast
blood
circul
detect
mild
case
earli
day
post
onset
symptom
symptom
subsid
sever
case
show
increas
plasmablast
symptom
began
resolv
earli
time
point
analyz
flow
cytometri
patient
evalu
kinet
bcell
epitop
mild
sever
cours
use
fullproteom
peptid
microarray
see
support
inform
complet
microarray
data
gener
trend
observ
viru
proteinspecif
iga
igg
respons
defin
signal
igm
show
signal
without
clear
trend
therefor
focus
iga
igg
respons
defin
normal
antibodi
background
neg
microarray
use
healthi
donor
sampl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
neg
control
sampl
select
th
percentil
fluoresc
intens
iga
arbitrari
fluoresc
unit
igg
arbitrari
fluoresc
unit
threshold
posit
igaand
iggreact
peptid
evolut
iga
igg
antibodi
target
peptid
patient
fig
fig
differ
time
point
show
differ
dynam
sever
case
patient
show
igaand
iggreact
peptid
control
sampl
threshold
consider
increas
toward
viru
clearanc
reactiv
iga
peptid
found
polyprotein
respons
becom
much
broader
diseas
progress
comparison
mild
case
patient
higher
number
igareact
peptid
alreadi
post
onset
symptom
show
decreas
number
reactiv
peptid
earli
time
point
alreadi
detect
defin
iga
epitop
spike
protein
patient
develop
iga
target
spike
epitop
trend
earli
iga
igg
antibodi
respons
also
observ
control
patient
moder
case
support
inform
figur
patient
mild
symptom
display
much
stronger
iga
respons
soon
onset
symptom
patient
patient
decreas
cours
diseas
day
later
igg
respons
similar
much
less
pronounc
trend
appear
persist
number
reactiv
igg
peptid
appear
lower
earli
acut
phase
comparison
iga
analyz
data
detail
toward
individu
protein
time
fig
day
patient
iga
antibodi
fig
target
polyprotein
iga
respons
still
low
turn
broad
respons
target
spike
membran
nucleocapsid
n
protein
iga
signal
increas
time
patient
three
signal
decreas
consider
might
result
nonprotect
crossreact
silenc
immun
system
contrast
patient
fig
igg
respons
alreadi
present
target
protein
patient
mild
symptom
fig
observ
stronger
focus
iga
respons
e
n
protein
compar
patient
wherea
igg
respons
fig
observ
one
stronger
respons
toward
protein
final
visual
signalsepitop
deriv
nine
patient
sampl
vs
control
sampl
n
protein
fig
support
inform
tabl
data
show
gener
iga
igg
igm
epitop
epitop
locat
n
protein
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
discuss
rapidli
spread
among
human
popul
sinc
end
knowledg
human
immun
respons
limit
factor
influenc
symptom
sever
larg
unknown
address
studi
kinet
bcell
epitop
develop
relat
clinic
immunolog
featur
two
patient
one
experienc
mild
diseas
cours
sever
patient
show
similar
viral
load
follow
infect
pfefferl
et
al
submit
proport
plasmablast
increas
earli
symptom
onset
decreas
patient
mild
diseas
cours
rel
plasmablast
frequenc
increas
patient
sever
diseas
cours
diseas
subsid
percentag
plasmablast
decreas
similar
observ
made
studi
posit
femal
patient
show
peak
cell
blood
day
post
diseas
onset
symptom
resolv
peptid
microarray
employ
obtain
comprehens
view
bcell
dynam
deeper
understand
develop
specif
bcell
epitop
cours
infect
investig
dynam
iga
igg
igm
antibodi
respons
mild
compar
sever
infect
acut
convalesc
phase
induct
earli
strong
antibodi
respons
recent
report
studi
seroconvers
occur
day
post
onset
symptom
infect
individu
anoth
studi
underlin
earli
respons
iga
igm
igg
follow
infect
author
report
median
durat
igm
iga
antibodi
detect
day
iqr
furthermor
okba
et
al
analyz
iga
igg
respons
two
mild
one
sever
case
use
inhous
observ
similar
trend
increas
iga
respons
time
sever
case
earli
iga
respons
seen
patient
observ
might
due
differ
patient
sampl
collect
date
assay
perform
key
differ
limit
use
elisa
vs
whole
proteom
microarray
higher
sensit
peptid
array
detect
earli
defin
iga
respons
patient
mild
cours
diseas
addit
patient
mildmoder
cours
diseas
hospit
see
support
inform
figur
also
show
earli
iga
respons
iga
consid
major
effector
molecul
involv
defens
mechan
virus
infect
respiratori
virus
induc
effici
iga
respons
secret
well
sera
data
suggest
iga
antibodi
valuabl
diagnost
marker
show
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
strong
signal
earli
onset
mild
symptom
iga
antibodi
may
crucial
effici
clearanc
identifi
mani
spike
protein
epitop
bound
iga
antibodi
might
crucial
neutral
viral
particl
earli
effici
bind
spike
protein
antibodi
limit
viral
spread
follow
infect
also
identifi
sever
iga
epitop
spike
protein
receptor
bind
domain
fusion
peptid
domain
addit
also
confirm
part
sarscov
crossreact
igg
epitop
receptor
bind
domain
spike
gener
microarray
valuabl
tool
identifi
crucial
antibodi
antigen
recent
patient
sampl
analyz
use
protein
array
well
wholeproteom
peptid
microarray
could
confirm
epitop
also
identifi
new
epitop
sinc
use
higher
number
peptid
sequenc
overlap
instead
amino
acid
data
give
comprehens
pictur
furthermor
show
iga
respons
may
highli
relev
diseas
progress
investig
analyz
low
number
patient
becom
avail
daili
array
contain
exclus
linear
peptid
identifi
antibodi
bind
conform
discontinu
epitop
peptid
overlap
amino
acid
mayb
short
overlap
insuffici
identifi
signific
antibodi
consid
exclus
initi
publish
wuhan
strain
without
mutat
quickli
incorpor
mutat
assay
sinc
array
product
method
rapid
flexibl
limit
list
studi
contribut
understand
differ
cours
diseas
patient
need
includ
followup
studi
evalu
import
earli
iga
respons
specif
epitop
develop
vaccin
futur
studi
consid
seroconvalesc
sampl
also
earli
time
point
collect
antibodi
dynam
bcell
epitop
studi
previous
present
first
longitudin
sampl
analysi
individu
bcell
epitop
develop
earli
diseas
phase
compar
degre
diseas
sever
data
start
point
develop
vaccin
therapeut
antibodi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
j
e
n
c
h
h
e
k
f
c
h
e
r
n
g
e
g
e
r
c
b
c
h
f
f
f
r
l
e
n
h
u
e
r
g
r
c
h
l
e
w
k
l
e
c
u
l
b
l
b
e
e
b
e
r
g
e
r
p
h
w
r
w
c
z
l
b
r
e
l
n
g
f
l
e
f
f
l
e
r
f
f
h
g
h
e
n
p
e
p
e
r
r
h
e
l
p
e
n
f
l
n
e
r
u
n
g
e
n
c
b
c
e
l
l
e
p
p
e
n
n
v
u
l
n
u
r
l
l
e
x
p
e
l
r
n
f
e
c
n
l
c
e
l
l
p
r
e
c
h
e
v
r
j
n
n
g
u
e
n
h
k
u
k
r
u
c
e
j
c
l
l
v
n
e
n
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
